On January 27, 2021 Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, reported that it will release thirteen new research findings at the 21st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31 (Press release, Genetron Health Technologies, JAN 27, 2021, View Source [SID1234574347]). One of the research findings (Study 3713) was selected for a mini oral presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Genetron Health joined hands with eight top Chinese hospitals to conduct in-depth analysis and research on a large-scale lung cancer cohort, leveraging the Genetron One-Step Seq Method and core products such as Onco PanscanTM. The research has achieved key findings in gene mutation and fusion feature mapping, immunotherapy marker detection, bioinformatics analysis, etc., laying the groundwork for further exploration of lung cancer diagnosis, treatment and the design of treatment solutions.
Exploring the characteristics of gene mutation
Seven studies (#1766, #2150, #2226, #2007, #1780, #1452, #835) on EGFR mutations, JAK family gene mutations, FGFR1-4 mutations, KIT activating mutations, mTOR signaling pathway mutations, and IDH1/2 mutations, respectively, were conducted to explore their mutation patterns and distribution characteristics in Chinese lung cancer patients, and to search for drug-resistant targets and effective solutions.
Exploring the characteristics of gene fusion
Study 3609 involved an in-depth analysis of 10 gene fusion patterns and distributions in the Chinese lung cancer population, as well as their co-occurrences with other driver mutations, in order to construct initial gene fusion mapping. Study 3601 focused on the prevalence and clinical benefit ratio of NTRK1 rare fusion in the Chinese lung cancer population.
Detecting immunotherapy markers
Study 3698 demonstrated the usage of KMT2C/D gene mutations as a positive predictor of the efficacy of non-small cell lung cancer (NSCLC) immunotherapy, indicating that patients with such gene mutations may benefit from immunotherapy. Study 3713 focused on the differences amongst DDR (DNA Damage Response) signaling pathway-related gene mutations in NSCLC and small cell lung cancer (SCLC), supporting the research of immunotherapy in the two patient groups.
Optimizing bioinformatics models
Based on six CpG sites, Study 2231 developed a random forest classification model, a new type of bioinformatics model, to distinguish early lung adenocarcinoma from benign nodules.
Rare case research
Study 3630 used Genetron’s One-Step Seq patented technology (Chinese Invention Patent No. ZL 201710218529.4) in the detection of a very rare patient with dual ROS1 fusion lung adenocarcinoma in a cohort of 180 people, demonstrating an efficacy greater than those of common diagnostic methods. In addition, the study noted the patient’s positive reaction to crizotinib, which indicates a direction for future research on the mechanism of this rare phenomenon.
"The thirteen research findings we are releasing at the WCLC, which focus on the characteristics of the Chinese lung cancer population, have made discoveries in multiple dimensions and demonstrated Genetron Health’s strong capabilities in the fundamental research of lung cancer genomics," said Dr. Hai Yan, Co-founder and Chief Scientific Officer of Genetron Health. "The research findings regarding EGFR, JAK, FGFR and other mutation patterns, and drug resistance studies can enhance the development of more diverse and personalized medication strategies for patients. Gene fusion mapping can guide the design of more advanced and rich diagnostic products. The discovery of KMT2C/D mutations indicates more possibilities for lung cancer patients to benefit from immunotherapy treatments. In addition, the rare cases detected through Genetron Health’s patented research technology will draw more attention to and promote further research on relevant cancer diagnosis and treatment."
ABSTRACT NUMBER
ABSTRACT TITLE
2226
Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing
3609
Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis
2150
Next generation sequencing reveals the genetic landscape of JAK family in Chinese lung cancer patients
1766
Comprehensive investigation of uncommon EGFR mutations in 14,429 Chinese lung cancer patients
1780
Next-generation sequencing guided the gene mutations associated with mTOR-inhibitors in Chinese lung cancer patients
3601
The prevalence of NTRK1 fusion in a Chinese lung cancer cohort
3630
A recommended one-step targeted sequencing technology for identification of a dual CD74-ROS1 in NSCLC
2231
Identification of DNA methylation markers to distinguish early-stage lung adenocarcinomas from benign pulmonary nodules
3713
DNA damage response gene alterations and their association with tumor mutation burden and response to immunotherapy in NSCLC and SCLC
3698
Association of KMT2C/D mutations with tumor mutation burden and response to immune checkpoint inhibitors in NSCLC
2007
Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients
835
Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
1452
A Large-Scale Survey of IDH Mutation in Chinese Patients With NSCLC